Stock Events

Stock Events

CrystalGenomics Invites 

₩1,340
2
-₩19-1.4% Today

Statistics

Day High
1,341
Day Low
1,338
52W High
2,290
52W Low
1,220
Volume
667,567
Avg. Volume
-
Mkt Cap
103.04B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

13MayExpected
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-58.79
-58.46
-58.13
-57.79
Expected EPS
N/A
Actual EPS
N/A

Financials

-710.63%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
14.51BRevenue
-103.09BNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 083790.KQ. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Ildong Pharm
249420.KQ
Mkt Cap0
ABL Bio Inc., focuses on therapeutic antibodies, directly competing in the biopharmaceutical sector where CrystalGenomics is also active.
Genexine
095700.KQ
Mkt Cap224.21B
Genexine, Inc. specializes in clinical-stage biotechnology, particularly in the development of biologics, aligning closely with CrystalGenomics' operations.
Medy-Tox
086900.KQ
Mkt Cap692.08B
Medy-Tox Inc., involved in biopharmaceuticals and healthcare, competes in the development of therapeutic solutions, similar to CrystalGenomics.

About

CrystalGenomics, Inc., a biopharmaceutical company, discovers and develops structural chemoproteiomics-based drugs in Korea. Its lead development candidate is NSAID (CG100649), which is a tissue specific anti-inflammatory agent with cardiovascular, gastrointestinal, and renal safety profiles that has completed Phase IIa clinical trial. The company's drug candidates also include CG200745, a histone deacetylase inhibitor for cancer, which is in Phase I clinical trial; and CG400549, an antibiotic candidate for methicillin resistant staphylococcus aureus and vancomycin resistant staphylococcus aureus, which is in Phase I clinical trial. In addition, it offers cloning, expression, purification, and characterization of proteins of interest; and assay and structure services. The company has drug discovery collaborations with AstraZeneca, Daiichi-Sankyo, SBI-Biotech, Carna Biosciences, Yuyu Pharma, AmorePacific, Hanmi Pharmaceuticals, and ProQuest Investments. CrystalGenomics, Inc. was founded in 2000 and is headquartered in Seongnam, South Korea.
Show more...
CEO
Willim Schmdit
Employees
65
Country
South Korea
ISIN
KR7083790006

Listings

KQ
KR
083790.KQ

0 Comments

Share your thoughts

FAQ

What is CrystalGenomics Invites stock price today?▼
The current price of 083790.KQ is ₩1,340 KRW — it has decreased by -1.4% in the past 24 hours. Watch CrystalGenomics Invites stock price performance more closely on the chart.
What is CrystalGenomics Invites stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange CrystalGenomics Invites stocks are traded under the ticker 083790.KQ.
Is CrystalGenomics Invites stock price growing?▼
083790.KQ stock has risen by +0% compared to the previous week, the month change is a -14.43% fall, over the last year CrystalGenomics Invites has showed a -35.11% decrease.
What is CrystalGenomics Invites market cap?▼
Today CrystalGenomics Invites has the market capitalization of 103.04B
What is CrystalGenomics Invites revenue for the last year?▼
CrystalGenomics Invites revenue for the last year amounts to 14.51B KRW.
What is CrystalGenomics Invites net income for the last year?▼
083790.KQ net income for the last year is -103.09B KRW.
How many employees does CrystalGenomics Invites have?▼
As of April 20, 2026, the company has 65 employees.
In which sector is CrystalGenomics Invites located?▼
CrystalGenomics Invites operates in the Health & Wellness sector.
When did CrystalGenomics Invites complete a stock split?▼
The last stock split for CrystalGenomics Invites was on April 01, 2021 with a ratio of 1.5:1.
Where is CrystalGenomics Invites headquartered?▼
CrystalGenomics Invites is headquartered in Seongnam-si, South Korea.